The FDA requires pharma manufacturers to include “New Drug Application” (NDA) data in some of their packaging inserts.  Here is an excerpt of the side effects data for Strattera:

Commonly observed adverse events in acute adult placebo-controlled trials — Commonly
observed adverse events associated with the use of STRATTERA (incidence of 2% or greater) and not observed at an equivalent incidence among placebo-treated patients (STRATTERA incidence greater than placebo) are listed in Table 2. The most commonly observed adverse events in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients) were: constipation, dry mouth, nausea, appetite decreased, dizziness, insomnia, decreased libido, ejaculatory problems, impotence, urinary hesitation and/or urinary retention and/or difficulty in micturition, and dysmenorrhea.

Source: Strattera NDA 21-411 (p. 16)  The NDA also includes other conditions that prompted subjects to drop out of the test.